How will Ranbaxy look different once Daiichi is in the driving seat?
As a company, Ranbaxy will always be run independently. The board will comprise of some people from Daiichi, some from the family and some independent directors. It will get reconstituted, but nothing changes in the operations of the company. In the management team, nobody comes from Japan. It will be the team I choose to have with the approval of the board. It is really our call on how to run the business. Certainly, the growth will be higher and so will be the size and scale of the investments. It is an aggressive company and you will see a lot more aggression in terms of leveraging opportunities for the next few years. Ranbaxy has no scientist or doctor on its board… We have a leading doctor on the board. In the past, we had Nitya Nand and he continues to work with us on the R&D side. He is on the scientific advisory board which meets on a yearly basis to gauge our scientists and work with them. You don’t need to have all the skill sets and capabilities at the board level but we n
